CN110628426A - 灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用 - Google Patents

灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用 Download PDF

Info

Publication number
CN110628426A
CN110628426A CN201810658496.XA CN201810658496A CN110628426A CN 110628426 A CN110628426 A CN 110628426A CN 201810658496 A CN201810658496 A CN 201810658496A CN 110628426 A CN110628426 A CN 110628426A
Authority
CN
China
Prior art keywords
hemorrhage
pain
rush
quantum dots
nano particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810658496.XA
Other languages
English (en)
Inventor
屈会化
赵琰
王庆国
孔慧
成金俊
张美龄
罗娟
熊威
朱雅凡
张越
鲁放
孙紫薇
闫昕
曹鹏
宋兴兴
王苏娜
王晓克
侯婷婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing University of Chinese Medicine
Original Assignee
Beijing University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing University of Chinese Medicine filed Critical Beijing University of Chinese Medicine
Priority to CN201810658496.XA priority Critical patent/CN110628426A/zh
Publication of CN110628426A publication Critical patent/CN110628426A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/44Elemental carbon, e.g. charcoal, carbon black
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00Nanooptics, e.g. quantum optics or photonic crystals
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/08Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
    • C09K11/65Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing carbon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

本发明涉及从灯心草炭中提取分离纯化出的量子点(纳米颗粒/纳米粒子)的方法,该方法包括:灯心草炭,经溶剂萃取或者提取,再用分子量大于1000Da的透析袋透析,或者超滤,得到灯心草炭量子点,该量子点在紫外灯365nm下呈蓝色荧光、透射电镜测量粒径<100nm,主要由C、H、O和N等元素构成;本发明还涉及此量子点在医药领域的应用,通过注射、口服或外用等途径给药后产生的止血、镇痛、镇静、抗炎、抗过敏、抗氧化、解热、解痉、降糖、降压、对抗肿瘤化疗药物的副反应等。

Description

灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用
技术领域
本发明属于医药技术领域,特别涉及灯心草量子点的制备及在医药领域的应用。
发明内容
本发明首次从灯心草中提取分离出量子点(纳米颗粒/纳米粒子),并首次发现了灯心草炭量子点具有很强的止血效应、抗炎等生物效应。
技术方案:本发明提供了从灯心草中提取分离出炭量子点的方法。本发明还提供了灯心草炭量子点的生物活性及其在医药领域中的应用。
所述制备方法,具体包括以下步骤:烘法制备灯心草,用溶剂从灯心草中提取出量子点,进一步分离纯化包括透析、超滤、层析等技术方法,得到高纯度的碳量子点。
附图说明
图1.灯心草炭断尾止血与肝脏止血统计图
图2.灯心草碳量子点透射电镜图及光谱图(A.灯心草炭低分辨电镜图;B.灯心草量子点粒径分布图;C.灯心草炭高分辨电镜图;D.灯心草碳量子点荧光光谱图; E.灯心草碳量子点紫外扫描图;F.灯心草碳量子点红外吸收图)
图3.XPS元素分析图
具体实施方式
实施例1:灯心草碳量子点的制备
称取干燥灯心草,置坩埚内,加盖,置马弗炉中,升温至250℃,保持恒温1h,待自然降温至室温,打开马弗炉取出,即为灯心草炭。
用纯水提取灯心草炭3次,合并水溶液,浓缩,用1KD透析袋透析,透析袋内的部分即为高纯度灯心草炭量子点的溶液。
待自然降温至室温,打开马弗炉取出,即为灯心草炭。用纯水提取灯心草3次,合并水溶液,浓缩,用10KD超滤管超滤,滤液即为高纯度灯心草炭量子点的溶液。
实施例3.灯心草碳量子点的止血作用
大鼠尾尖止血:
1.实验的前一晚禁食12小时,正常给水。实验当天先将老鼠称重,分为为生理盐水组;阳性药组;高剂量组;中剂量组;低剂量组。
2.将标号的小鼠分装好,待用。实验前两小时分别给药,以充分吸收药物。实验前半小时给麻醉。尾尖止血实验采用剪尾法,首先麻醉好的小鼠的尾长测量好,然后统一在尾尖一厘米处测量小鼠尾巴的直径,到给药两小时后剪尾,观察并记录小鼠尾尖的出血时间并做好记录。
3.结果见表1,高中低三个剂量与正常组相比均具有明显的断尾止血作用,尤其是高剂量组与蛇凝血酶对照组的止血效果相当。
大鼠肝脏止血:
1.实验的前一晚禁食12小时,正常给水。实验当天先将老鼠称重标号。
2.实验前两小时给药,实验前半小时麻醉,待小鼠麻醉后,将小鼠四肢固定,腹部充分的暴露,沿腹中线将小鼠腹部破开,肝脏充分的暴露,避免伤及胸腔。用生理盐水将肝脏冲洗干净,并用纱布将水吸干。将肝脏底部铺上纱布以固定,然后用2ml的针头扎肝脏的左叶距边缘约0.5cm,进针0.3cm,观察并记录出血时间。
3.结果见图1,高中低三个剂量与正常组相比均具有明显的断尾止血与肝脏止血作用,尤其是高剂量组与蛇凝血酶对照组的止血效果相当。

Claims (7)

1.一种从灯心草炭中提取纯化出量子点的方法。
灯心草炭的制备方法包括直火烧法、锅炒法、闷煅法、烘法等。经溶剂萃取或者提取后,再用分子量为1KDa-10KDa的透析袋透析,透析袋内截留的部分,或者用10KD的超滤管超滤,滤液部分。该量子点的特征:在紫外灯365nm下呈蓝色荧光、透射电镜测量粒径1-100nm,主要由C、O和Fe元素构成。
2.灯心草炭量子点在医药领域的应用。
包括但不限于止血、镇痛、镇静、抗炎、抗过敏、抗氧化、解热、解痉、降糖、降压、对抗肿瘤化疗药物的副反应。
3.根据权利要求1所述的灯心草炭的制备方法,其特征在于干馏法的温度为100-1500度。提取溶剂为水、甲醇、乙醇、乙酸乙酯、甲酸乙酯、乙酸甲酯、丙酮、***、氯仿、石油醚中的一种或几种混合溶剂。
4.根据权利要求3所述的灯心草炭的制备方法,其特征在于干馏法的温度为200-500度。
5.根据权利要求1所述量子点的粒径为1-20nm。量子点的元素组成包括但不限于C、H、O和N元素。
6.根据权利要求2所述的应用,其剂型为注射剂、注射用粉针、口服液体制剂、硬胶囊、软胶囊、片剂、栓剂、水丸、蜜丸、浓缩丸、膏剂、散剂、乳剂、糊剂、涂抹剂等。
7.根据权利要求2所述的应用,治疗或预防的病证为:各种出血病证、血管爆裂、脑出血、肝出血、肺出血、肾出血、脾出血、胆道出血、视网膜出血、鼻出血、口腔出血、消化道出血、胃出血、肠出血、直肠出血、产后出血、子宫出血、手术后出血、外伤出血等;内伤或外伤性疼痛、癌症疼痛、头痛、眼痛、耳痛、鼻痛、口腔疼痛、皮肤疼痛、心脏疼痛、肝痛、胃痛、肺痛、内脏疼痛、四肢疼痛;过敏性鼻炎、哮喘、湿疹、荨麻疹、紫癜、药物过敏、食物过敏、紫外线过敏、过敏体质、各种过敏和类过敏;躁狂症、失眠、焦虑、抑郁;发烧、不明原因的高烧、低烧;烧伤、烫伤、抽搐、癫痫、高血压、糖尿病、肿瘤化疗药物所致的头痛恶心呕吐等症、水肿、中风等。
CN201810658496.XA 2018-06-22 2018-06-22 灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用 Pending CN110628426A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810658496.XA CN110628426A (zh) 2018-06-22 2018-06-22 灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810658496.XA CN110628426A (zh) 2018-06-22 2018-06-22 灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用

Publications (1)

Publication Number Publication Date
CN110628426A true CN110628426A (zh) 2019-12-31

Family

ID=68967094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810658496.XA Pending CN110628426A (zh) 2018-06-22 2018-06-22 灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用

Country Status (1)

Country Link
CN (1) CN110628426A (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290784A (ja) * 2005-04-08 2006-10-26 Yukihiro Hirose 血流悪化防止作用を有する組成物、及びそれを含有する飲食品
CN1895291A (zh) * 2006-06-09 2007-01-17 陈永丽 纳米中药生物制品及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290784A (ja) * 2005-04-08 2006-10-26 Yukihiro Hirose 血流悪化防止作用を有する組成物、及びそれを含有する飲食品
CN1895291A (zh) * 2006-06-09 2007-01-17 陈永丽 纳米中药生物制品及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEILING ZHANG ET AL.,: "Novel carbon dots derived from Schizonepetae Herba Carbonisata and investigation of their haemostatic efficacy", 《ARTIFICIAL CELLS,NANOMEDICINE, AND BIOTECHNOLOGY》 *
王建中: "灯心草炭炮制方法述略", 《浙江中医杂志》 *

Similar Documents

Publication Publication Date Title
CN102212093B (zh) 黄酮苷类化合物及其制备方法和用途
WO2006063515A1 (fr) Utilisation de radix sanguisorbae et de son extrait pour la preparation d’un medicament visant a accroitre la numeration erythrocytaire et le taux d’hemoglobine
CN104513290B (zh) 雷醇内酯衍生物及其应用
CN110623992A (zh) 艾叶炭量子点(纳米颗粒/纳米粒子)的制备及其应用
CN102579554A (zh) 花生茎叶提取物及其制备方法用途
CN110624011B (zh) 焦山楂碳量子点(纳米颗粒/纳米粒子)的制备及其应用
CN110628426A (zh) 灯心草炭量子点(纳米颗粒/纳米粒子)的制备及其应用
CN1939421A (zh) 一种抗菌、抗病毒的中药组合物
TW201109023A (en) Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of colorectal cancer
CN110623997A (zh) 黄芩炭量子点(纳米颗粒/纳米粒子)的制备及其应用
CN111249362A (zh) 一种治疗褥疮、糖尿病足、皮肤或粘膜创伤、痔疮的中药组合物、中药制剂及其制备方法
CN110623996A (zh) 荆芥穗炭量子点(纳米颗粒/纳米粒子)的制备及其应用
CN105362407A (zh) 一种预防和/或治疗吸烟导致的亚健康的组合物
CN110051817A (zh) 一种降低尿酸的中药组合及其应用
CN110623990A (zh) 小蓟炭量子点(纳米颗粒/纳米粒子)的制备及其应用
CN107158302B (zh) 一种用于保护胃粘膜的天然药物组合物及其制备方法
CN108096318A (zh) 治疗心脑血管疾病的药物组合物及其制备方法和用途
CN105796764B (zh) 黄荆子总木脂素制备方法及其用途
WO2015172273A1 (zh) 控制人体血脂和体重的药物组合物及其应用
CN103566349B (zh) 一种治疗高血糖高血脂的药物组合物
CN102204956B (zh) 一种用于中风恢复期的中药组合物及其制备方法
CN110755486A (zh) 一种治疗鼻渊的麻杏石甘汤加味中药组方
CN101564418B (zh) 一种治疗口腔溃疡的药物组合物
CN101502536B (zh) 香柏总黄酮及其制备方法与医药用途
CN110628424A (zh) 麦芽炭碳量子点(纳米颗粒/纳米粒子)的制备及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191231

WD01 Invention patent application deemed withdrawn after publication